DeSantis group reports 41% stake in Integrated BioPharma

Integrated BioPharma Inc. received an updated ownership report showing concentrated control of its common stock.

Rhea-AI Filing Summary

Integrated BioPharma Inc. received an updated ownership report showing concentrated control of its common stock. CDDS 2.0, LLC now holds 12,733,058 shares, about 41.0% of the company’s 31,059,610 outstanding shares as of April 15, 2026. Damon DeSantis is deemed to beneficially own 12,920,558 shares, or 41.3%, through CDDS and 187,500 presently exercisable stock options held directly. These positions arose from internal transfers from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis to CDDS for no cash consideration. The reporting group states it currently has no plans involving mergers, asset sales, control changes, or other actions listed in Item 4, while reserving the right to change its intentions.

Insights

Equity Ownership & Governance Analyst

Schedule 13D shows over 41% ownership via internal transfers, with no stated activism plans.

CDDS 2.0, LLC now controls 12,733,058 shares of Integrated BioPharma common stock, about 41.0% of outstanding shares as of April 15, 2026. Through CDDS and 187,500 stock options, Damon DeSantis is reported as beneficial owner of 12,920,558 shares, or 41.3%.

The filing explains that these shares were consolidated into CDDS from CD Financial, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis for no cash consideration, indicating an internal restructuring rather than market buying. The group reports no contracts or arrangements regarding the issuer’s securities other than DeSantis’s stock options.

The group states it does not currently plan transactions such as mergers, major asset sales, or changes in control under Item 4, but explicitly reserves the right to change its intentions based on future circumstances. Subsequent ownership reports or company disclosures would clarify any future strategic moves tied to this concentrated stake.

Key Figures

CDDS share ownership: 12,733,058 shares DeSantis beneficial ownership: 12,920,558 shares Shares outstanding: 31,059,610 shares +4 more

7 metrics

CDDS share ownership 12,733,058 shares Common stock beneficially owned by CDDS 2.0, LLC; 41.0% of class

DeSantis beneficial ownership 12,920,558 shares Common stock beneficially owned by Damon DeSantis; 41.3% of class

Shares outstanding 31,059,610 shares Integrated BioPharma common stock outstanding as of April 15, 2026

Stock options held by DeSantis 187,500 shares Presently exercisable stock options directly held by DeSantis

Transfer from CD Financial on Mar 24, 2026 1,356,293 shares Common shares transferred from CD Financial, LLC to CDDS

Transfer from CD Financial on Apr 15, 2026 8,966,547 shares Common shares transferred from CD Financial, LLC to CDDS

Transfer from Revocable Trust on Apr 15, 2026 2,235,417 shares Common shares transferred from Carl DeSantis Revocable Trust to CDDS

Key Terms

beneficial owner, sole voting power, dispositive power, stock options, +2 more

6 terms

beneficial owner financial

"DeSantis is the beneficial owner of an aggregate of 12,920,558 shares of Common Stock"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

sole voting power financial

"CDDS has sole voting power and sole dispositive power with respect to the 12,733,058 shares"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"shared voting power and shared dispositive power with respect to the 12,733,058 shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

stock options financial

"DeSantis directly holds 187,500 shares of Common Stock in the form of presently exercisable stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Schedule 13D regulatory

"If the filing person has previously filed a statement on Schedule 13G"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Joint Filing Agreement regulatory

"99.1 Joint Filing Agreement, as required by Rule 13d-1 (k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Integrated BioPharma (INBP) shares does CDDS 2.0, LLC own?

CDDS 2.0, LLC is the record and beneficial owner of 12,733,058 Integrated BioPharma common shares. This represents approximately 41.0% of the 31,059,610 shares outstanding as of April 15, 2026, giving CDDS significant voting and dispositive control over the company’s equity.

What is Damon DeSantis’s beneficial ownership in Integrated BioPharma (INBP)?

Damon DeSantis is reported as beneficial owner of 12,920,558 Integrated BioPharma common shares. This equals about 41.3% of the 31,059,610 shares outstanding as of April 15, 2026, combining his control of CDDS 2.0, LLC and 187,500 presently exercisable stock options held directly.

How were the Integrated BioPharma (INBP) shares acquired by CDDS and DeSantis?

The shares were acquired through internal transfers for no cash consideration. Stock moved from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis into CDDS 2.0, LLC. The filing states no funds were used, borrowed, or obtained to acquire, hold, trade, or vote these shares.

Does the DeSantis group plan any control changes at Integrated BioPharma (INBP)?

The group states it currently has no plans or proposals for actions listed in Item 4, such as mergers, major asset sales, or control changes. However, it reserves the right to change its intentions in the future depending on relevant factors and circumstances affecting its investment.

What voting and dispositive power does CDDS 2.0, LLC have over INBP shares?

CDDS 2.0, LLC reports sole voting and sole dispositive power over 12,733,058 Integrated BioPharma common shares. Through control of CDDS, Damon DeSantis has shared voting and dispositive power over those shares, and sole voting and dispositive power over 187,500 additional shares via stock options.

Did the DeSantis group trade Integrated BioPharma (INBP) shares recently in the market?

The filing notes that, aside from the internal transfers detailed in Item 3, neither member of the group effected any transaction in Integrated BioPharma common shares during the 60 days before the statement date. This suggests the reported position reflects internal restructuring rather than recent market trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/17/2026 - 03:48 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

INTEGRATED BIOPHARMA INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

Damon DeSantis
109 SE 5th Avenue, Second Floor
Delray Beach, FL, 33483
561-278-1169

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/15/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP No.

1

Name of reporting person

DeSantis Damon

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 187,500.00
8	Shared Voting Power 12,733,058.00
9	Sole Dispositive Power 187,500.00
10	Shared Dispositive Power 12,733,058.00

11

Aggregate amount beneficially owned by each reporting person

12,920,558.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

41.3 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No.

1

Name of reporting person

CDDS 2.0, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 12,733,058.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 12,733,058.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

12,733,058.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

41.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: INTEGRATED BIOPHARMA INC
(c)	Address of Issuer's Principal Executive Offices: 225 LONG AVENUE, BUILDING 15, HILLSIDE, NEW JERSEY , 07205.
Item 2.	Identity and Background
(a)	(i) CDDS 2.0, LLC, a Florida limited liability company ('CDDS') (ii) Damon DeSantis, an individual ('DeSantis', and, together with CDDS, the 'Group')
(b)	(i) CDDS: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483 (ii) DeSantis: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483
(c)	(i) CDDS: N/A (ii) DeSantis: Retired
(d)	N/A
(e)	N/A
(f)	(i) CDDS is a limited liability company organized under the laws of the State of Florida. (ii) DeSantis is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	The shares of Common Stock reported herein were acquired in the following three-step sequence for no cash consideration: (a) On March 24, 2026, March 30, 2026 and April 15, 2026, 1,356,293, 150,000 and 8,966,547 shares of Common Stock, respectively were transferred from CD Financial, LLC, a Florida limited liability company, to CDDS; (b) On March 24, 2026 and April 15, 2026, 7,392 and 2,235,417 shares of Common Stock, respectively, were transferred from the Carl DeSantis Revocable Trust to CDDS; and (c) On March 30, 2026, 17,409 shares of Common Stock were transferred from the Estate of Carl DeSantis to CDDS. DeSantis controls CDDS as its sole member. No funds or other consideration was used by either member of the Group to acquire the shares of Common Stock subject hereof, and no funds or other consideration were borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the shares of Common Stock subject hereof.
Item 4.	Purpose of Transaction
	No member of the Group has a present intention or plans or proposals which relate to or could result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. Notwithstanding anything to the contrary contained herein, each member of the Group reserves the right, depending on all relevant factors, to change their intentions with respect to any and all of the matters referred to above.
Item 5.	Interest in Securities of the Issuer
(a)	After giving effect to the transfers described in Item 3: (i) CDDS is the record and beneficial owner of 12,733,058 shares of Common Stock, representing approximately 41.0% of the outstanding shares of Common Stock (based on 31,059,610 shares of Common Stock outstanding as of April 15, 2026). (ii) DeSantis is the beneficial owner of an aggregate of 12,920,558 shares of Common Stock, representing approximately 41.3% of the outstanding shares of Common Stock (based on 31,059,610 shares of Common Stock outstanding as of April 15, 2026). DeSantis does not directly hold the shares of Common Stock described in the transfers set forth in Item 3. DeSantis directly holds 187,500 shares of Common Stock in the form of presently exercisable stock options.
(b)	(i) CDDS has sole voting power and sole dispositive power with respect to the 12,733,058 shares of Common Stock. (ii) Through control of CDDS, DeSantis has shared voting power and shared dispositive power with respect to the 12,733,058 shares of Common Stock described in Item 3. DeSantis has sole voting power and sole dispositive power with respect to the 187,500 shares of Common Stock beneficially owned by DeSantis.
(c)	Except for the transactions described in Item 3, neither member of the Group has effected any transaction in the shares of Common Stock subject hereof during the sixty (60) days prior to the date of this Statement.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Neither member of the Group has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer of voting of securities, finder's fees, joint venture, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses or the giving or withholding of proxies, other than stock options issued by the Issuer to DeSantis.
Item 7.	Material to be Filed as Exhibits.
	99.1 Joint Filing Agreement, as required by Rule 13d-1 (k) under the Securities Exchange Act of 1934, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DeSantis Damon

Signature:	/s/ Damon DeSantis
Name/Title:	Damon DeSantis/Individual
Date:	04/17/2026

CDDS 2.0, LLC

Signature:	/s/ Damon DeSantis
Name/Title:	Damon DeSantis/Sole Member
Date:	04/17/2026